

DERMAPURE® SIGNALS A NEW DIRECTION IN SOFT TISSUE REGENERATION

A next-generation decellularized dermal allograft



DERMA **[PURE]**
dCELL technology

NOT ALL SURGICAL GRAFTS ARE CREATED EQUAL

All soft tissue surgical grafts have a purpose and function for surgeons, but not every graft can deliver on multiple procedural needs.

SURGICAL GRAFT GOALS

Repair & Replace

OR

Reconstruct & Structurally Support

What if there was a graft that could meet multiple needs of the surgeon, regardless of procedure?



GRAFT TAKE




GRAFT INTEGRATION



GRAFT HANDLING

Choose DermaPure® for a surgical graft without compromise.

Add the allograft designed to meet your needs and signal a confident outcome.



DERMA [PURE]
dCELL technology


DERMAPURE® ENABLES GRAFT TAKE

After application, DermaPure® impacts soft tissue revascularization at the surgical site by signaling cellular migration and proliferation.



DermaPure® is an intact extracellular matrix with vascular-like channels necessary for revascularization.

DermaPure® retains collagens, proteoglycans, glycosaminoglycans, and other extracellular matrix proteins.



DermaPure® provides an access point for proliferation of native cells, including endothelial cells and fibroblasts.

x20 magnification

- **DCD** - DermaPure®
- **EC** - Endothelial Cells
- **Fb** - Fibroblast
- **F** - Subcutaneous fat
- **GT** - Granulation Tissue
- **Black dotted line** - border between DermaPure® and host tissue

7

DermaPure® facilitates the re-establishment of vascular channels, providing an access point to signal cellular activity enabling successful graft take in just seven days.¹

DERMAPURE® PROMOTES GRAFT INTEGRATION

Skin substitutes differ in many ways: tissue source, processing methodologies, patient response — and surgeon use.

Xenografts

- Enhanced biomechanical strength, but less organized. Non-human matrix provides less infiltration for vascular integration
- Cross-linking of xenograft tissue can inhibit cell migration and proliferation
- Disorganized granulation tissue vessels are rapidly replaced by fibrotic tissue¹


Autografts

- Prolonged operating room time with tissue harvesting and implantation
- Native tissue procured for target procedure may be insufficient and require follow-up procedure
- Patient comorbidities can affect the quality of tissue harvested and associated integration


DermaPure® is a human-derived acellular matrix that has been demonstrated to provide **higher pro-angiogenic response during integration** with reduced fibrosis compared to Integra™ (xenograft) and control (secondary intention).¹

REVASCULARIZATION:

Higher Quantity with DermaPure®



Higher Quality with DermaPure®




DermaPure® integrates with and closely approximates the structure and function of native tissue.²

Autograft

Displays retention of normal ECM architecture and minimal fibrosis



- **A** - Autograft
- **FN** - Fibrotic Neodermis.
- **E** - Epidermis



DermaPure®

Illustrates dense cellular infiltration, partial rete ridge reformation, uniform fibrosis, and **could not be distinguished from native dermis** once infiltrated by host cells.

- **DCD** - DermaPure®
- **ND** - Native Dermis
- **RR** - Rete Ridges
- **FN** - Fibrotic Neodermis
- **E** - Epidermis



Integra (Xenograft)

- Displays a dense, thick band of fibrosis and remains visibly present.
- Structural differences with xenograft group influences the distribution and organization of the vascular network required for integration.

- **CG** - Integra
- **FN** - Fibrotic Neodermis
- **E** - Epidermis

DERMAPURE® OPTIMIZES GRAFT HANDLING

DermaPure® is a thin, decellularized dermal allograft with enhanced handling and suturability that doesn't trade off strong biomechanical properties.

DERMAPURE® BIOMECHANICAL PERFORMANCE³

Biomechanical Test*	Thickness**	Ultimate Tensile Strength	Tensile Maximum Load	Tensile Elastic Modulus	Tensile Stiffness	Burst Maximum Load	Burst Maximum Pressure	Suture Peak Load
Metric	mm	MPa	N	MPa	N/mm	N	N/cm ²	N
DermaPure®	1.06 - 1.16	22.7	132.0	69.6	18.7	364.3	1,022.4	50.0
Market Leader 1.0 mm	1.00 - 1.18	16.4	81.3	52.8	10.8	368.4	1,033.8	47.7
Market Leader 1.5 mm	1.34 - 1.76	12.3	89.4	40.7	12.8	361.7	1,015.2	47.7
Market Leader 2.0 mm	1.80 - 2.00	22.6	214.6	62.5	24.6	682.5	1,915.6	84.5

- Values statistically significantly lower than DermaPure®
- No statistically significant difference from DermaPure®
- Competitor values statistically significantly higher than DermaPure®

*Tissue Regenix data on file; all results are mean values
 **Mean thickness range of samples measured prior to biomechanical testing

Biomechanical Test Definitions

- Ultimate Tensile Strength (UTS)** – Maximum resistance to failure and load carried by one square unit area (stress).
- Tensile Maximum Load** – Maximum load used to calculate UTS; this result is dependent on the size & thickness of test specimen.
- Tensile Elastic Modulus** – The measure of a material's resistance to being deformed elastically (i.e. non-permanently) when a stress is applied to it.
- Tensile Stiffness** – The measure of a material's resistance to being deformed when a load is applied to it.
- Burst Maximum Load & Pressure** – Measure of force and pressure required to rupture or puncture specimen.
- Suture Peak Load** – Maximum force that can be applied before a suture pulls through the specimen.



dCELL® TECHNOLOGY IS THE DIFFERENCE

Not all tissue processing is the same: each process utilizes different methods.

Unlike alternative tissue processes, dCELL® Technology is a unique, proprietary, and patented process that produces high-quality, decellularized donor tissue with nearly no structural disruption and promotes regeneration.

	dCELL® Technology	Alternative Processes*
Remove Donor Cells and Cellular Debris	Uses extremely low concentration of single anionic detergent (SDS-0.01%) to remove donor cells and cellular debris	<ul style="list-style-type: none">• Anionic detergents (NLS, SDS) can damage structural and mechanical properties of tissue⁴• Tissue integrity can be affected by number of anionic detergents used, concentration, and duration used during processing• Intact cells still present in donor tissue⁵
Remove DNA	Utilizes a nuclease treatment that results in >99% DNA removal ³	<ul style="list-style-type: none">• Lack of nuclease treatment results in incomplete DNA removal• Residual DNA may trigger immunogenic response that could lead to failure or complications
Preserve Tissue Structure	Use of protease inhibitors helps preserve native tissue structure and biomechanical properties ⁶	<ul style="list-style-type: none">• Tissue structure and biomechanical properties may be altered when protease inhibitors are not utilized• Limits potential to promote regeneration
Neutralize Pathogens and Microbial Sterility	<ul style="list-style-type: none">• Terminally irradiated to provide a sterility assurance level (SAL) of 10^{-6} for neutralization, essentially eliminating all pathogens• Reduces risk of further contamination and disease transmission⁷• Provides microbial sterility	<ul style="list-style-type: none">• Aseptically processed tissue yields an SAL of 10^{-3}• May not eliminate the inherent microbial bioburden in tissue⁷

*Based on review of patents and scientific literature

dCELL® Technology delivers on each of the fundamentals of Tissue Decellularization that sets it apart from other biologic options.

- **Low concentration of SDS** to remove donor cells and cellular debris, while preserving tissue integrity
- **Nuclease treatment** for near complete DNA removal
- **Protease inhibitors** to preserve tissue structure, tissue integrity, and biomechanical properties
- **Terminally irradiated** to neutralize and eliminate pathogens to provide microbial sterility

DERMAPURE® SIGNALS A NEW DIRECTION IN SOFT TISSUE REGENERATION

- Minimally manipulated to preserve tissue structure
- Signals cell migration and proliferation
- Increases angiogenesis and reduces fibrosis
- Optimal handling and biomechanical strength in a thin profile biologic

DermaPure® is available in the following sizes:

SKU	Size
010200HD	1 cm x 2 cm
020200HD	2 cm x 2 cm
020300HD	2 cm x 3 cm
030400HD	3 cm x 4 cm
040600HD	4 cm x 6 cm
071000HD	7 cm x 10 cm
0071000HDN	7 cm x 10 cm (Non-Oriented)
07100HDMESH	7 cm x 10 cm (Unstretched)
091200HD	9 cm x 12 cm

A next-generation decellularized dermal allograft

DERMA [PURE]
dCELL[®] technology



**1808 Universal City Blvd
Universal City, Texas 78148
1-833-567-0767
TissueRegenixUS.com**

1. Creaves NS, Iqbal SA, Morris J, et al. Acute cutaneous wounds treated with human decellularised dermis show enhanced angiogenesis during healing. PLoS ONE. 2015;10(1):e0113209. **2.** Creaves NS, Bayat A (2015). Skin Substitute-Assisted Repair Shows Reduced Dermal Fibrosis in Acute Human Wounds Validated Simultaneously by Histology and Optical Tomography. Wound Rep Reg (2015) 23 483-494. **3.** Data on file at Tissue Regenix. **4.** Srokowski EM, Woodhouse KA. Decellularized scaffolds. In: Ducheyne P, ed. Comprehensive Biomaterials. New York, NY: Elsevier; 2011:369-386. **5.** Carruthers CA, Dearth CL, Reing JE, et al. Histologic characterization of acellular dermal matrices in a porcine model of tissue expander breast reconstruction. Tissue Engineering Part A. 2014;21(1-2):35-44. **6.** Booth, C, et al. Tissue engineering of cardiac valve prostheses I: development and histological characterization of an acellular porcine scaffold. J Heart Valve Dis. 2002;11(4):457-462. **7.** Singh R, Singh D, Singh A. Radiation sterilization of tissue allografts: a review. World J Radiol. 2016;8(4):355-369. doi:10.4329/wjrv.8.4.355.

Tissue Regenix Wound Care, Inc. is doing business as TRX BioSurgery
TRX BioSurgery, Tissue Regenix Wound Care, Inc. and Tissue Regenix Wound Care Limited are part of the Tissue Regenix Group
DermaPure® is a registered trademark of Tissue Regenix Wound Care Limited.
dCELL[®] Technology is a registered trademark of Tissue Regenix Limited.
Integra[™] Wound Matrix is a registered trademark of Integra LifeSciences Corporation.